STAT Plus: Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst

STAT Plus: Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

Tocagen pitched the study?s continuation as an encouraging sign for its gene therapy, but its stock price fell sharply.